Alumis (ALMS) Current Deferred Revenue (2025)

Alumis' (ALMS) quarterly Current Deferred Revenue came in at $1.5 million in Q4 2025.

Alumis (ALMS) Current Deferred Revenue (2025) Analysis & Trends

Alumis (ALMS) has 1 years of Current Deferred Revenue data on file, last reported at $1.5 million in Q4 2025.

On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $1.5 million in Q4 2025; TTM through Dec 2025 was $1.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $1.5 million, changed N/A from the prior year.
Current Deferred Revenue for Q4 2025 stood at $1.5 million.
Over the last five years, Current Deferred Revenue for ALMS reached as high as $1.5 million in Q4 2025 and fell as low as $1.5 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Alumis	2.41 Bn	2.10 Bn	-

Download Data

Date	Value
Dec 31, 2025	1.46 Mn